ClinicalTrials.gg
RecruitingNCT00055172Updated Nov 12, 2026

Genetic Basis of Immunodeficiency

An observational study in Severe Combined Immunodeficiency, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 6 Months to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational

How we know

From the registry’s dates

  • Started Apr 2004; still recruiting 22 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
100
Ages
6 Months to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Severe Combined Immunodeficiency with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Severe Combined Immunodeficiency · United States.

Planned enrollment
5th of 12
100 · median 88
Started
2004
with 1 other
Observational
12 of 38
5 open now
Registered
7th of 38
by date
Lead sponsor
2 of 38
National Heart, Lung, and Blood Institute (NHLBI)

Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2004, is one of 12 observational ones, and was the 7th registered.

Severe Combined Immunodeficiency

59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.

Browse Severe Combined Immunodeficiency studies →

Open to participants now

9 of the 38 studies in Severe Combined Immunodeficiency with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Severe Combined Immunodeficiency studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 6 Months to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Severe Combined Immunodeficiency with a site in United States, or all of them as a file.
02

Study summary

This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID).

Patients with immunodeficiencies may be eligible for this study. Candidates include:

  • Patients with diminished numbers of T cells or NK cells or both, or
  • Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function.

Relatives of patients will also be studied.

Participants will have blood samples collected for genetic analysis in studies related to SCID at the National Institutes of Health and other institutions.

...

Read the detailed description

The goal of this project is to identify the genetic basis of new forms of inherited immunodeficiency. The particular focus relates to cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 that share the common cytokine receptor (Gamma) chain, (Gamma c), and to molecules that are important for signaling or gene regulation in response to these cytokines, although other causes of inherited immunodeficiency are also encompassed.

03

Conditions studied

  • Severe Combined Immunodeficiency

Keywords

  • Cytokines
  • Inherited Immunodeficiency
  • Natural History
04

Who can participate

Ages eligible
6 Months to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary clinical

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index cases to be included are those with diminished numbers of T cells and/or NK cells and/or B cells or other immune cells or those who have normal numbers of T cell, B cells, NK cells and other immune cells but diminished function of one or more immune cells. Relatives of affected individuals may also be studied

  • Patients (index cases): 6 months of age and older
  • Siblings: 6 months of age and older
  • Non-sibling relatives (biological parent, aunt, uncle or grandparent): 18 years or older

Exclusion criteria

EXCLUSION CRITERIA:

  • Patients with a known diagnosis
  • Patients with a particular immunological phenotype that is not of interest to the research conducted under this study.
  • Pregnancy or lactation
  • Adults with current decisional impairment
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)

Groups and cohorts

  • Non-sibling relative

    18 years of age or older

  • Patients (index cases)

    Patients (index cases), 6 months of age or older

  • Siblings

    Siblings, 6 months of age or older

06

What researchers measure

Primary outcomes

  1. To identify forms of inherited immunodeficiency resulting from mutation of yc dependent cytokines, components of their receptors, or signaling molecules in their pathways

    In an effort to determine the cause of the immunodeficiency, we will perform studies that may include but not be limited to evaluating the levels of expression of protein and/or mRNA, obtaining DNA sequence data, performing epigenetic studies, and evaluating biological function using cellular, biochemical, or other molecular studies.

    Time frame: ongoing

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993 Apr 9;73(1):147-57. doi: 10.1016/0092-8674(93)90167-o. PubMed 8462096 ↗
  • Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995 Nov 3;270(5237):797-800. doi: 10.1126/science.270.5237.797. PubMed 7481768 ↗
  • Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998 Dec;20(4):394-7. doi: 10.1038/3877. PubMed 9843216 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

7 registry updates since Sep 25, 2026

Started Apr 2004 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2003
First posted
Feb 20, 2003
StartActual
Apr 5, 2004
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description and verification date
7 updates, last Nov 12, 2026
Show all 7 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 10, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  4. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  5. Nov 3, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  7. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00055172
Responsible party
Sponsor
First posted
Feb 20, 2003
Start date
Apr 5, 2004
Last update
Nov 12, 2026

Study contacts

Warren J Leonard, M.D.
Contact
wl2w@nih.gov
(301) 496-0098
Warren J Leonard, M.D.
principal investigator · National Heart, Lung, and Blood Institute (NHLBI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion